GUIDED HEALTH REFILL

Two Ways to Fix IBD Trials: Change the Therapy, or Change the Measurement

A clear, practical guide designed to help you understand the topic, measure the options and choose a useful next step.

PATHWAYHealth
SESSION LENGTH2 minutes
LAST REVIEWEDNov 2, 2026
IBD clinical trials
2MIN REFILL
Evidence-aware resource

Progress in inflammatory bowel disease (IBD) depends on two things: treatments that work, and trials that can tell whether they do. Two recent developments attack those problems separately, and together they show where the field is heading.

A microbiome-based approach to colitis

Microbiotica has reported notable clinical results from its MB310 trial in colitis. MB310 is a microbiome-based therapeutic designed to modulate gut flora and restore immune balance. The reported results point to promising efficacy signals and support the growing role of microbiome science in IBD treatment strategies.

The gut-immune connection is well studied, but turning it into a treatment is harder than describing it. If larger studies confirm the early picture, microbiome therapeutics could sit alongside traditional biologic and small-molecule treatments instead of competing with them. The report on Microbiotica’s MB310 colitis trial has the specifics.

Better measurement through digital pathology

In IBD, microscopic disease activity plays a central role in judging response. Traditionally that judgment relies on pathologists reading slides, and two experts can disagree. PathAI has expanded its AISight platform to support pathology assessment in IBD clinical trials.

AI-driven pathology tools can improve consistency, reduce inter-observer variability and produce more precise histologic endpoints. Standardized digital assessment may also speed data interpretation and increase regulatory confidence. The expansion of PathAI’s AISight for IBD trials reflects a wider move toward data-enhanced precision.

Why both matter at once

A strong therapy measured with a noisy endpoint can look weaker than it is. A precise endpoint applied to a weak therapy simply produces a clear negative. Progress needs both: a mechanism worth testing and a way to read the result without argument.

What to watch

For MB310, the key question is whether the efficacy signals hold in larger and longer studies. For AISight, it is whether sponsors and regulators accept standardized digital scoring as a primary measure. Neither answer is in yet, and both will shape how IBD studies are designed.

What patients may notice first

Most patients will never see a histology score. What they may eventually notice are the downstream effects: therapies evaluated on cleaner data, and treatment options that reflect more than one immune mechanism. For someone whose current treatment has stopped working, a new category of therapy and a more reliable way to test it are both welcome developments. Together they suggest the field is willing to question long-held habits in how IBD is studied.

Conclusion

IBD research is improving on two fronts at once. New biology gives patients more potential options, and better measurement helps the field recognize which of those options deserve to move forward.